Pharma · Acute pain medicines · Hospital-level launch
We launch acute pain medicines, and reposition pharma brands at hospital level.
Your launch is in pain medicine, or your brand needs to land at hospital level rather than die in the formulary committee at features-and-benefits level. We've spent five years specialising in both, inside one of EU pharma's most innovative manufacturers. Fourteen programmes shipped. MLR-cleared at first review on most of them. The mechanics that broke pharma marketing don't break the work we've built around them.
You're not short of assets. You're short of attention.
Your brand has a deck for every specialty, a slide for every objection, and a congress plan three meetings deep. What it doesn't have is the rep time in front of a prescriber to land any of it. The average HCP gives the entire supplier market under ten minutes of attention across an entire year. And when they listen, it's because the rep earned the slot with something useful, not because medical affairs scheduled it.
Pain medicine launches run the same playbook as every other category. Big congress booth. Expensive symposium. KOL advisory board. Targeted rep call plan. That playbook hits forecast about a quarter of the time. The rest spend three years recovering a shortfall they predicted in week six. The launches that perform are not the ones that spend more. They are the ones that frame the medicine around the formulary committee's actual question, how does this reduce length of stay, medication errors, opioid escalation, or the cost of our pain pathway, not the molecule's properties.
And the compliance machinery that should protect the brand ends up throttling it. Four rounds of review to land a LinkedIn post. A congress activation signed off two days before the congress opens. Creative that starts brave and finishes beige because the strongest sentence got cut at round three. Not where we work. Five years, fourteen programmes, mostly cleared at first review.
The regulations haven't changed. The workflow has. Brave work gets through when you build the workflow for it.
Where you're launching matters
These are the pharma situations we know deepest.
Start small. Most pharma teams do.
Getting started.
Workshop
£2K
One-day deep dive into a specific challenge. Less than a single MLR review costs you. Most pharma teams start here.
Diagnostic
£5K
Written assessment of where you are and what to fix first. The qualification step before any larger commitment.
Programme
From £15K
Focused engagement: launch, congress, patient, or sales enablement. Scoped to one specific outcome.
Full 3 E’s
From £25K
Six-month strategic and execution programme. Empower, Evolve, Equip across the launch system.
Questions your brand team and procurement will ask. Answers we've already prepared.
Do you have pain-medicine experience specifically?
Acute pain is the pharma category we know deepest. Sublingual analgesia, prefilled-syringe analgesics, hospital pain protocols, and a research partnership with the University of Bath on Painful Conversations, the clinician guide to high-stakes pain conversations with patients. Five years continuous commercial work in this category.
What evidence can you show?
Five years of continuous commercial work for one of EU pharma's most innovative manufacturers. Fourteen separate programmes across brand identity, formulary submission, congress activation, KOL engagement, patient marketing, and sales enablement. 340% congress ROI on a specialist launch. Sales conversion moved from 18% to 31% on a second-line therapy. Client name under NDA, we speak to the work in detail on a triage call.
How do you handle ABPI, EFPIA and FDA compliance?
We operate inside the frameworks, not around them. Our SAFE methodology brings regulatory people into the concept stage, not the sign-off stage. That is where the compression in review cycles comes from. Most of our work clears MLR at first review.
Have you worked across multiple EMEA markets?
Yes. UK, EU5, and US. The commercial architecture translates. The messaging and regulatory layer adapts to each market's reality, and we scope that explicitly per programme.
How does your pricing work?
Project-based or retainer. No hourly billing. Every engagement has a scope and a deliverable. ROI is modelled before we begin, not reported afterwards. The £2K workshop and £5K diagnostic are designed as low-friction entry points so we both know we fit before any larger commitment.
Can you work alongside our existing agency roster?
Regularly. We often take the demand-generation and strategic piece and hand the execution to agencies the brand already trusts. Clear lanes. Fewer arguments.
How does this sit with our internal medical team?
They stay in control of medical content. We build the commercial and creative layer that sits on top of it. Clearer lanes, fewer arguments, faster sign-off.
What is the University of Bath research partnership?
A formal academic collaboration that produced Painful Conversations, a clinician-facing guide on managing high-stakes pain conversations with patients. The research is published, citable, and freely usable as evidence in your own communications. The full guide is hosted on this site.
What changes when the demand engine works.
Prescribers you had not called on start asking the rep about your medicine. Because they saw something your KOL shared, read something your patient campaign surfaced, or sat next to someone at congress who was talking about it. Rep access stops being a function of call plans and becomes a function of pull.
MLR review cycles compress because creative and compliance are reading the same brief. Board presentations shift from defending marketing spend to explaining where the next quarter of pipeline is coming from. Launch forecasts get hit more often than missed, because the system learns in month two rather than crashing in month twelve. The formulary committee starts asking how to make the case for the medicine, instead of asking what makes it different from the incumbent.
A pharma launch that performs isn't one that spends more. It's one built for how acute pain medicines actually reach patients now.
The commercial playbook built for the attention economy of 2010 is running into an attention economy that isn't that any more. Rep access isn't coming back. Compliance isn't getting looser. Congress attendance isn't rising. Pretending those things will revert is the most expensive strategy in the industry right now.
The pharma companies pulling ahead over the next three years will have redesigned their commercial model around the new reality. They'll spend less on sales headcount and more on demand. They'll treat compliance as a creative parameter, not a creative limit. They'll reposition their brands around the hospital-level outcome the formulary committee is buying for, not the molecule's properties.
Every quarter spent defending the old model is a quarter your competitor spends building the next one.